- Dosage: 15mg Artemether per 5mL
- Volume: 60 ml bottle
- Packaging: 60 ml bottle/box*300 carton
- Shelf Life: 36 months
Package:
Product Description
Product Overview
Artemether Suspension 15mg/5mL is an oral liquid formulation containing artemether, a semisynthetic derivative of artemisinin. Artemether is the methyl ether of dihydroartemisinin, which is itself derived from artemisinin, a naturally occurring compound isolated from the leaves of Artemisia annua L. (sweet wormwood). Each 5mL of the suspension provides 15mg of artemether in a palatable, easy-to-administer liquid form.
Artemether Suspension 15mg/5mL 60mL: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
This page collects the supply-relevant facts for Artemether Suspension 15mg/5mL 60mL — specification, testing, packaging and the registration paperwork that travels with the batch.
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
These points are quoted because they shape how Artemether Suspension 15mg/5mL 60mL is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.
Artemether Suspension 15mg/5mL 60mL — Supply Parameters
| Product Name | Artemether Suspension |
| Specification | 15mg/5mL, 60mL bottle |
| Dosage Form | Oral Suspension |
| Active Ingredient | Artemether |
| Route of Administration | Oral |
| Storage | Store below 25°C, protected from light and moisture. Do not freeze. Keep bottle tightly closed when not in use. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Artesunate Suspension 10mg/5mL 80mL, Artemether-Lumefantrine Suspension 180/1080mg, Artesunate Suppositories 100mg, Artemether 80mg Injection, Artesunate 20mg + Pyronaridine 60mg Granules, Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg.
Quality Control, Pharmacopoeial Standards & Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Artemether Suspension 15mg/5mL 60mL is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
A typical release panel for this presentation covers:
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packaging, Labelling & Export
- Pack size: 60mL amber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, protected from light and moisture. Do not freeze. Keep bottle tightly closed when not in use..
- Shelf life: 24 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Registration, Dossier & Tender Support
Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
This page describes Artemether Suspension 15mg/5mL 60mL as a product of the ACT regimens named in the WHO Model List of Essential Medicines family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.
Frequently Asked Questions
What pack size is available for Artemether Suspension 15mg/5mL 60mL?
The reference pack is 60mL amber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.
What documentation comes with a shipment of Artemether Suspension 15mg/5mL 60mL?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months.
Does the batch documentation for Artemether Suspension 15mg/5mL 60mL support a registration filing?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
What is the difference between artesunate and artemether for injection?
Artesunate is the WHO drug of choice for severe malaria and may be given intravenously or intramuscularly at 2.4 mg/kg. Artemether is an alternative given intramuscularly at 3.2 mg/kg on admission then 1.6 mg/kg daily, and must never be given intravenously.
Which ACT combinations appear on the WHO Model List?
The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.
Related Malaria & ACTs Products
- Artesunate Suspension 10mg/5mL 80mL — 10mg/5mL
- Artemether-Lumefantrine Suspension 180/1080mg — 1080mg
- Artesunate Suppositories 100mg — 100mg
- Artemether 80mg Injection — 80mg
- Artesunate 20mg + Pyronaridine 60mg Granules — 20mg
- Chloroquine Phosphate 500mg Tablets — 500mg
Browse the full Malaria & ACTs range; all Suspensions; the complete product catalogue.
Request a Quotation for Artemether Suspension 15mg/5mL 60mL
Send the specification, pack size, quantity and destination market for Artemether Suspension 15mg/5mL 60mL 15mg/5mL and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.
Sources & Regulatory Notes
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- WHO — Malaria case management: operations manual
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
